# Icosavax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/icosavax

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.icosavax.com
- Total disclosed funding: $130M
- Latest round: Series B (Mar 19, 2021)
- Investors on record: 11

## About

Founded in 2018 and based in Washington, US, Icosavax, Inc. operates as a biotechnology company that develops vaccines using computationally designed proteins. The company was co-founded by CEO Adam Simpson and David Baker Ph.D. Icosavax has raised a total of USD 161 million from investors including Sanofi Ventures, Qiming Venture Partners, RA Capital Management, Bill & Melinda Gates Foundation, Viking Global Investors and Omega Funds. In December 2023, AstraZeneca acquired Icosavax, Inc. from Adams Street Partners, Logos Capital, RA Capital Management, Sanofi Ventures, TCG Crossover Management, Vivo Capital, and Qiming Venture Partners for USD 1.1 billion.

Icosavax is focused on developing vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses that address important unmet medical needs. Icosavax is also developing VLP vaccine candidates against the respiratory syncytial virus (RSV), human metapneumoviru­­s (hMPV), and SARS-CoV-2 (COVID-19). These vaccine candidates have shown induction of neutralizing antibody titers in preclinical studies and could protect the most vulnerable populations, including older adults.

Icosavax, Inc. plans to advance IVX-121 into clinical studies within 2021 and study IVX-121 in young and older adults that will enable the transition to a bivalent RSV/hMPV clinical program.

## Funding rounds

- Series B, Mar 19, 2021, $100M — Adams Street Partners, Qiming Venture Partners, Viking Global Investors, +ND Capital, Omega Funds, Sanofi Ventures, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, Janus Henderson Investors, Surveyor Capital
- Series A, Oct 3, 2019, $30M — Adams Street Partners, Qiming Venture Partners, +ND Capital, Sanofi Ventures

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A, Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Janus Henderson Investors — Series B
- Surveyor Capital — Series B